RevMed's Daraxonrasib Gets Standing Ovation at ASCO
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Daraxonrasib received a standing ovation from oncologists during its data presentation at the American Society of Clinical Oncology (ASCO) meeting.
- Leanna Stokes shared how participating in Revolution Medicines’ daraxonrasib trial impacted her metastatic pancreatic cancer and life on the “Readout LOUD” podcast.
- Abivax presented ulcerative colitis data at ASCO, sparking a market reaction discussed on the podcast.
- American Diabetes Association is slated to hold its meeting soon, as highlighted in the podcast preview.
Why it matters: Metastatic pancreatic cancer patients receive a therapy that impressed oncologists, while biotech investors see stock declines; the market reaction to Abivax data underscores volatility in specialty drug sectors.
Ask SkimNews
